⚠️ FDA Notice: Compounded GLP-1 medications are not FDA-approved. The FDA is currently proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list.
Clinical Evidence

GLP-1 for Heart Failure: The STEP-HFpEF Data Nobody Talks About

· 8 min read

Most people know GLP-1 medications for weight loss. Some know about the cardiovascular benefits from the SELECT trial, or the kidney protection from the FLOW trial. But the data that may matter most to millions of Americans gets almost no mainstream attention: semaglutide produced dramatic improvements in heart failure — not by preventing it, but by treating it directly.

The Heart Failure Type Nobody Understands

Heart failure with preserved ejection fraction — HFpEF (pronounced "hef-pef") — is one of the most common and most frustrating conditions in cardiology. The heart pumps blood normally in terms of squeeze strength (preserved ejection fraction), but the chamber walls have stiffened, making it unable to fill properly. The result: debilitating symptoms including severe shortness of breath, fatigue, fluid retention, and dramatically reduced exercise capacity.

HFpEF accounts for roughly half of all heart failure cases, its prevalence is increasing, and — until STEP-HFpEF — there were essentially no effective treatments specifically targeting it. Unlike heart failure with reduced ejection fraction (HFrEF), which has a well-established drug regimen, HFpEF has been a therapeutic dead end for decades.

Here's the connection: approximately 60% of HFpEF patients have the obesity phenotype. Excess body weight contributes to systemic inflammation, increased blood volume, and the mechanical loading that drives cardiac stiffness. Obesity-related HFpEF is now recognized as a pathophysiologically distinct form of the disease — and it's the form that GLP-1 medications appear to treat.

STEP-HFpEF: The Trial Design

The STEP-HFpEF trial, published in the New England Journal of Medicine, enrolled 529 patients across 96 sites in 13 countries. All had confirmed HFpEF with obesity (BMI ≥30). Participants were randomized to semaglutide 2.4 mg weekly or placebo for 52 weeks.

The trial measured two primary endpoints: change in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), which captures patient-reported symptoms and physical limitations, and change in body weight. Secondary endpoints included 6-minute walk distance, C-reactive protein (a marker of systemic inflammation), and a hierarchical composite that included death, heart failure events, and functional outcomes.

The Results

The data was striking across every measured outcome:

Symptom improvement. Semaglutide produced a KCCQ-CSS increase of 16.6 points versus 8.7 points for placebo — a clinically meaningful difference. For context, a 5-point change in KCCQ-CSS is considered clinically significant. The semaglutide group nearly doubled the placebo response.

Weight loss. Patients on semaglutide lost 13.3% of body weight compared to 1.8% on placebo over 52 weeks.

Inflammation reduction. C-reactive protein — a key driver of HFpEF pathology — dropped 43.5% with semaglutide versus 7.3% with placebo. This is a massive reduction in systemic inflammation, suggesting the drug does more than just reduce weight.

Exercise capacity. The 6-minute walk distance improved more with semaglutide, though the absolute difference was modest. For patients with severe functional limitations, any improvement in exercise tolerance translates directly to quality of life.

Hierarchical composite. Semaglutide was favored over placebo on all components — death, heart failure events, symptom improvement, and walking distance — with an overall win ratio of 1.72 (95% CI 1.37–2.15, p<0.001).

NT-proBNP. This cardiac biomarker, which rises when the heart is under stress, decreased 20.9% with semaglutide versus 5.3% with placebo. This suggests genuine disease-modifying effects beyond symptom management.

Safety. Serious adverse events occurred in 13.3% of the semaglutide group versus 26.7% in the placebo group — semaglutide patients experienced fewer serious events, not more.

STEP-HFpEF DM: The Diabetes Subgroup

A companion trial, STEP-HFpEF DM, enrolled 616 patients who had HFpEF, obesity, and type 2 diabetes — a particularly challenging population with worse baseline function and higher event rates. The results were consistent: KCCQ-CSS improved 13.7 points versus 6.4 on placebo, and weight decreased 9.8% versus 3.4%. NT-proBNP reductions were also favorable, and the distribution of heart failure hospitalizations and urgent visits favored semaglutide.

Why This Data Gets Overlooked

STEP-HFpEF should be headline news. Here's a drug that dramatically improved symptoms, exercise capacity, inflammation, and cardiac biomarkers in a condition with essentially no other effective treatment. The likely reasons it hasn't gotten the attention it deserves:

HFpEF isn't as "clean" a narrative as weight loss or cardiovascular risk reduction. It's a complex condition that most people have never heard of. The outcomes — quality-of-life scores, walk tests, biomarkers — don't translate to the kind of dramatic before-and-after numbers that drive media coverage.

Additionally, the trial wasn't powered for mortality. While the hierarchical composite included death and the direction favored semaglutide, the number of deaths was small. A dedicated heart failure outcomes trial is needed to confirm whether semaglutide reduces actual mortality in HFpEF — not just symptoms.

The Broader Pattern: GLP-1 as Multi-Organ Therapy

STEP-HFpEF fits into a growing body of evidence that GLP-1 medications affect far more than body weight:

The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in patients with obesity but without diabetes.

The FLOW trial showed 24% reduction in kidney disease progression — so significant the trial was stopped early.

SURMOUNT-OSA demonstrated improvements in obstructive sleep apnea with tirzepatide, leading to reductions in CPAP use.

SURMOUNT-5 confirmed tirzepatide's superiority over semaglutide for weight loss specifically, but the multi-organ benefit pattern applies to the entire GLP-1 class.

Taken together, GLP-1 agonists are emerging as a new class of cardiometabolic therapy — not just a weight loss drug, not just a diabetes drug, but a treatment that addresses the inflammatory and metabolic dysfunction underlying multiple chronic conditions simultaneously.

What Patients Should Take Away

If you have heart failure with preserved ejection fraction — especially if you also have obesity — the STEP-HFpEF data is directly relevant to your care. Semaglutide is not currently FDA-approved specifically for HFpEF, but the evidence supports a conversation with your cardiologist about whether GLP-1 therapy could address both your weight and your heart failure symptoms.

For prescribers, the 43.5% CRP reduction and the 20.9% NT-proBNP reduction suggest disease-modifying effects that go beyond the weight loss benefit alone. The safety profile — fewer serious adverse events in the treatment group — removes one of the common hesitations about prescribing semaglutide in patients with cardiac comorbidities.

Further analyses from the STEP-HFpEF program have shown consistent benefits across age groups, obesity classes, and whether body weight reduction was large or modest. The effects are robust and appear to be driven by mechanisms beyond caloric reduction alone.

Compare GLP-1 Providers & Pricing

See current pricing from verified telehealth providers offering GLP-1 medications.

Compare Providers →

Sources

Related Articles

Clinical

GLP-1 and Kidney Protection: The FLOW Trial Data

 Head-to-Head

Zepbound vs Wegovy: SURMOUNT-5 Settled the Debate